Drug Approval | October 09, 2022
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
The company increases its efficiency and is able to face the growing demand for its services.
The company increases its efficiency and is able to face the growing demand for its services.
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
The inspection concluded with no observation (FDA-483) issued.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Subscribe To Our Newsletter & Stay Updated
